1 |
Mariette X, Gottenberg JE. Pathogenesis of Sjögren′s syndrome and therapeutic consequences [J]. Curr Opin Rheumatol, 2010, 22(5): 471-477.
|
2 |
Båve U, Nordmark G, Lövgren T, et al. Activation of the type Iinterferon system in primary Sjögren′s syndrome: a possible etiopathogenic mechanism [J]. Arthritis Rheum, 2005, 52(4): 1185-1195.
|
3 |
Gottenberg JE, Cagnard N, Lucchesic, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren′s syndrome [J]. Proc Natl Acad Sci USA, 2006, 103(8): 2770-2775.
|
4 |
Vogelsang P, Brun JG, Oijordsbakken G, et al. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren′s syndrome [J]. Ann Rheum Dis, 2010, 69(6): 1235-1238.
|
5 |
Vitali C, Bombardiere S, Jonsson R, et al.Classification criteria for Sjögren′s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group [J]. Ann Rheum Dis, 2002, 61(6): 554-558.
|
6 |
Sahu R, Bethunaickan R, Singh S, et al. Stucture and function of renal macrophages and dendritic cells from lupus-prone mice [J]. Arthritis Rheumatol, 2014, 66(6): 1596-1607.
|
7 |
Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren,s syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren′s related lymphomagenesis [J]. Autoimmun, 2015, 63: 47-58.
|
8 |
Yang L, Bai L, Wei F, et al. Autoantibodies against interferon-γ reduce the frequency of pulmonary fibrosis and concentration of creactive protein in patients with primary Sjogren,s syndrome [J]. Mod Rheumatol, 2015, 25(2): 325-327.
|
9 |
李晓玲,汪国生,赵小娟, 等. 原发性干燥综合征患者外周血浆细胞样树突状细胞变化 [J]. 中华微生物学和免疫学杂志, 2015, 35(2): 117-120.
|
10 |
Gottenherg JE, Caguard N, Lucehesi C, et a1. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren′s syndrome [J]. Proc Nail Acad Sci USA, 2006, 103(8): 2770-2775.
|
11 |
Sawai CM, Sisirak V, Ghosh HS, et al. Transcription factor Runx 2 controls the development and migration of plasmacytoid dendritic cells [J]. J Exp Med, 2013, 210(11): 2151-2159.
|
12 |
Shen L, Suresh L, Malyavantham K, et a1. Different stages of primary Sjogren′s syndrome involving lympho-toxin and type 1 IFN [J]. J Lmmunol, 2013, 191(2): 608-613.
|
13 |
Rahaman O, Bhattacharya R, Liu CSC, et al. Cutting edge: dysregulated endocannabinoid-rheostat for plasmacytoid dendritic cell activation in a systemic lupus endophenotype [J]. Immunol, 2019, 202(6): 1674-1679.
|
14 |
Kupriyanov SV, Sinitskii AI. Pleiotropic functions of plasmacytoid dendritic cells in the pathogenesis of the rheumatoid arthritis [J]. Med Hypotheses, 2019, 122(1): 26-30.
|
15 |
Ainola M, Porola P, Takakubo Y, et al. Activation of plasmacytoid dendritic cells by apoptotic particles-mechanism for the loss of immunological tolerance in Sjögren′s syndrome [J]. Clin Exp Immunol, 2018, 191(3): 301-310.
|